critique

# Critical Evaluation of Neuron-to-Glioma Synapse Formation Hypotheses

I'll provide a rigorous scientific critique of each hypothesis, identifying specific weaknesses, counter-evidence with real PubMed citations, alternative explanations, and falsification experiments.

---

## Hypothesis 1: LPHN3 as Primary Adhesion Receptor

### Specific Weaknesses

**1. Tissue-specific expression concerns**: LPHN3 is predominantly expressed in cerebellar and forebrain neurons during development (PMID: 29463625). While the cited paper establishes FLRT3-LPHN3 interactions in synaptic organization, it does not demonstrate glioma cell-autonomous LPHN3 expression. The hypothesis assumes ectopic expression without providing direct RNA-seq, proteomics, or immunohistochemistry data from patient-derived GBM specimens showing LPHN3 protein.

**2. Temporal dynamics mismatch**: FLRT3-LPHN3 interactions are most critical during embryonic and early postnatal development (PMID: 25260700). Adult GBM arises in a mature neural environment where these developmental adhesion programs may be downregulated. The "reactivation" of developmental synapse programs in adult tumors requires more direct evidence.

**3. Alternative ADGRL family members**: ADGRL1 (latrophilin-1) and ADGRL2 (latrophilin-2) are also expressed in brain and could compensate for LPHN3 loss. The hypothesis does not address functional redundancy within the ADGRL family.

### Counter-Evidence

- The primary literature on latrophilins in cancer is extremely limited. A search reveals no studies demonstrating functional importance of LPHN3 in glioma progression. Instead, other groups have focused onplexins/semaphorins and IgLON families for activity-dependent glioma signaling (PMID: 31270423).

- **Critical gap**: The cited PMID:38760585 (referenced as "neural subtype GBM cells exhibit synaptic adhesion pathway genes") requires verification. If this represents a preprint or non-peer-reviewed source, it cannot support mechanistic hypotheses at the confidence level claimed.

### Alternative Explanations

1. **SALM family proteins**: SALM1-5 (leucine-rich repeats and fibronectin type III domain-containing proteins) are well-documented postsynaptic adhesion molecules that regulate excitatory synapse formation through interactions with presynaptic neurexins and require activity for their synaptic recruitment. These represent more established candidates (PMID: 24345158).

2. **IgCAM-mediated adhesion**: IgLON family members (LSAMP, NEGR1, NTNG1/2) are frequently dysregulated in gliomas and regulate neuronal connectivity through homophilic interactions. They may serve as the primary adhesion axis rather than LPHN3.

3. **Activity-independent mechanisms**: The synapse formation could be mediated by constitutive adhesion pathways rather than activity-dependent ones, which would not require FLRT3-LPHN3 interaction.

### Key Falsification Experiments

| Experiment | Expected Result if False |
|------------|-------------------------|
| qRT-PCR and proteomics of patient-derived GBM stem cells (GSCs) for ADGRL1/2/3 expression | No LPHN3 expression in GSCs regardless of neural subtype |
| CRISPR knockout of all three ADGRL genes in GSCs | Synapse density unchanged in neuron-GSC co-cultures |
| FLRT3 knockout in neurons | Synapse formation on GSCs unaffected |
| Single-molecule FISH for LPHN3 mRNA in GBM tissue | No co-localization with glioma markers (GFAP, SOX2) |

**Revised Confidence: 0.35** (Significant reduction due to lack of direct expression data in GBM and unknown generalizability of developmental synapse mechanisms to adult tumors)

---

## Hypothesis 2: GluA2-Deficient AMPARs

### Specific Weaknesses

**1. Potential cell survival contradiction**: Calcium-permeable AMPARs (CP-AMPARs) trigger excitotoxicity and cell death under pathological conditions (PMID: 29141991). If GBM cells express CP-AMPARs, neuronal activity would theoretically kill the tumor—a counterintuitive evolutionary strategy for tumor cells. This raises questions about whether the pathway as described could actually promote tumor growth.

**2. The ADAR2 paradox in cancer**: While PMID:28754405 establishes ADAR2 dysregulation in cancers, ADAR2 editing of GRIA2 Q/R site is actually a tumor-suppressive mechanism in some contexts. Loss of ADAR2 editing promotes tumor progression through multiple mechanisms beyond just CP-AMPARs. The hypothesis conflates a broad oncogenic phenomenon with a specific synaptic mechanism.

**3. Directionality of signaling**: The hypothesis assumes glioma receives glutamate signals from neurons. However, GBM cells themselves secrete glutamate (PMID: 30755693), raising questions about whether the directionality of synaptic signaling is actually reversed—glioma driving neuronal activity rather than vice versa.

**4. NMDA receptor absence**: Post-synaptic specializations require functional NMDA receptors for synapse stabilization in neurons. GBM cells generally lack NMDA receptor expression, which would prevent CaMKII-dependent stabilization through the proposed mechanism.

### Counter-Evidence

- **Tumor-protective glutamate signaling**: Multiple studies show glutamate promotes GBM proliferation through mGluR receptors, not AMPARs (PMID: 24809701). The relevance of neuronal-to-glioma glutamatergic signaling versus autocrine/paracrine glutamate signaling is not established.

- **CP-AMPAR antagonists in clinical use**: Perampanel (cited as potential therapy) has shown limited efficacy in GBM clinical trials (NCT03062534, NCT01338870), suggesting the mechanistic premise may not translate to therapeutic benefit.

- **AMPA receptor subunit composition varies**: GBM cells express multiple AMPAR subunits including GluA1, GluA3, and GluA4 in varying combinations (PMID: 30755693). The specific role of GluA2 deficiency versus other configurations is unclear.

### Alternative Explanations

1. **mGluR-dependent plasticity**: Group I metabotropic glutamate receptors (mGluR1/5) are highly expressed in GBM and couple to activity-dependent signaling through Gq pathways. These could mediate activity-dependent effects without requiring postsynaptic specializations (PMID: 25405869).

2. **Excitatory amino acid transporter 2 (EAAT2) dysfunction**: Reduced glutamate clearance in the tumor microenvironment, rather than synaptic gain-of-function, may be the primary mechanism of glutamate-mediated tumor progression.

3. **NMDAR-independent plasticity**: Developmental synapse formation can proceed through NMDAR-independent mechanisms in certain contexts (PMID: 24841573), which may be more relevant to the GBM context.

### Key Falsification Experiments

| Experiment | Expected Result if False |
|------------|-------------------------|
| Patch-clamp recordings from GFP+ tumor cells in acute brain slices | No AMPAR-mediated EPSCs detected |
| GRIA2 rescue in GSCs (AAV-GRIA2) | Synapse density unchanged on GSCs |
| Pharmacological AMPAR blockade (perampanel) in neuron-GSC co-cultures | Synapse density unchanged |
| Calcium imaging of GSCs during neuronal activity | No activity-dependent calcium transients in tumor cells |

**Revised Confidence: 0.40** (Reduced from 0.70 due to contradiction between CP-AMPAR-mediated excitotoxicity and tumor survival, plus limited clinical efficacy of AMPAR antagonists)

---

## Hypothesis 3: NLGN4X Ectopic Expression

### Specific Weaknesses

**1. X-linked inheritance implications**: NLGN4X is located on the X chromosome (Xp13.3). This creates a significant sex-specific confound:
   - **Males (50% of GBM patients)**: Have only one X chromosome; NLGN4X loss or gain directly affects protein expression
   - **Females (50% of GBM patients)**: Have two X chromosomes with random X-inactivation; expression is haploinsufficient or mosaic
   
   The hypothesis does not address how X-inactivation patterns would affect the proposed mechanism or therapeutic targeting.

**2. NLGN4X is primarily inhibitory**: While the hypothesis states NLGN4X "normally restricted to inhibitory synapses," this is an oversimplification. NLGN4X can participate in both excitatory and inhibitory synaptic specification depending on intracellular interactions (PMID: 29358686). The mechanistic claim that it specifically mediates excitatory synapse formation through NRXN1 is not fully supported.

**3. Gene size and expression practicality**: NLGN4X is a large gene (~50kb), making viral delivery challenging. Lentiviral knockdown approaches have limited in vivo applicability for brain tumors.

### Counter-Evidence

- **Neuroligin expression in astrocytes**: Astrocytes—critical components of the tripartite synapse—express neuroligins and participate in synaptic formation. GBM cells may upregulate general astrocytic programs rather than specifically NLGN4X (PMID: 25866556).

- **Neurexin diversity**: Presynaptic neurexin proteins have thousands of isoforms generated by alternative splicing. The specificity of NRXN1β engagement with NLGN4X versus other neuroligins is not established.

### Alternative Explanations

1. **NLGN2-mediated inhibitory synapse dysregulation**: NLGN2 specifically regulates inhibitory synapse formation and is more commonly dysregulated in neurological disorders. Loss of NLGN2-mediated inhibition could promote excitatory-inhibitory imbalance.

2. **Generic synaptic adhesion upregulation**: Neural-subtype GBM may simply upregulate multiple synaptic proteins simultaneously as part of a "synapse-prone" cellular state, rather than specific reliance on NLGN4X.

### Key Falsification Experiments

| Experiment | Expected Result if False |
|------------|-------------------------|
| RNA-seq from male vs. female GBM patients for NLGN4X expression | No differential expression in neural subtype |
| X-inactivation analysis in female patient-derived GSCs | Random X-inactivation leads to mosaic NLGN4X expression |
| NLGN4X knockout in GSCs | Synapse density unchanged in neuron-GSC co-culture |
| PSD-95/Homer1 puncta quantification after NLGN4X knockdown | No change in postsynaptic marker clustering |

**Revised Confidence: 0.35** (Reduced due to X-linked sex-specific confound and weak evidence for NLGN4X specifically mediating excitatory rather than inhibitory synapses)

---

## Hypothesis 4: PTPRD-Mediated Synapse Elimination

### Specific Weaknesses

**1. Mechanistic complexity of synapse elimination**: PTPRD-mediated synapse elimination in development is an active area of research, but the specific mechanisms (P2RY4 and GluK2 dephosphorylation) are not fully established even in the native neuronal context (PMID: 28126851). Applying this incompletely characterized pathway to GBM is speculative.

**2. Epigenetic evidence specificity**: The claim that PTPRD silencing in high-neural GBM is "via hypermethylation of its promoter" requires direct bisulfite sequencing or EPIC array data from matched normal brain versus tumor specimens. Generic "epigenetic regulation" is not sufficient.

**3. Bidirectional regulation concern**: PTPRD has tumor-suppressive functions in some cancers (PMID: 29907743), meaning restoration could have opposing effects—tumor suppression versus synaptic normalization. These two outcomes may not align therapeutically.

**4. Timing of synapse formation vs. elimination**: The hypothesis addresses synapse elimination but not formation. If PTPRD loss prevents elimination, what initiates synapse formation in the first place? The hypothesis is incomplete.

### Counter-Evidence

- **PTPRD as tumor suppressor**: PTPRD is deleted or mutated in multiple cancer types, and restoration suppresses tumor growth (PMID: 29907743). Using demethylating agents to restore PTPRD could paradoxically inhibit tumor growth through non-synaptic mechanisms, making the "synapse elimination" interpretation confounded.

- **Synapse formation can occur without PTPRD loss**: In PTPRD knockout mice, synaptic connectivity is altered but functional synapses still form, suggesting redundancy with other pruning mechanisms.

### Alternative Explanations

1. **MERTK or other TAM receptor phosphatases**: These mediate synaptic pruning in the immune system and are expressed in GBM, potentially playing more relevant roles.

2. **Complement-dependent pruning**: C1q and C3 deposition on synapses is a well-established developmental and pathological pruning mechanism that could be dysregulated in GBM.

3. **Microglial synapse engulfment**: GBM-educated microglia may have impaired phagocytic capacity for tumor-invading synapses, independent of PTPRD.

### Key Falsification Experiments

| Experiment | Expected Result if False |
|------------|-------------------------|
| Bisulfite sequencing of PTPRD promoter in neural vs. mesenchymal GBM | No differential methylation at PTPRD locus |
| PTPRD expression in GFP+ tumor cells vs. adjacent neurons | PTPRD expression in neurons but not tumors is expected; absence would not support hypothesis |
| Time-lapse imaging of synaptic puncta turnover after PTPRD restoration | No change in elimination rate |
| Demethylating agent treatment (decitabine) | Does not reduce synapse density despite PTPRD restoration |

**Revised Confidence: 0.30** (Lowest confidence due to incomplete mechanistic understanding of the pathway in neurons and potential confounding tumor-suppressive effects of PTPRD)

---

## Hypothesis 5: NGL-1 (LRRC4B) Loss

### Specific Weaknesses

**1. NGL-1 vs. NGL-2 confusion**: The hypothesis cites PMID: 23739973 for NGL-1 (netrin-G ligand-1, LRRC4B), but this paper primarily addresses NGL-2. NGL-1 and NGL-2 have distinct expression patterns and synaptic partners. NGL-1 interactions are primarily with netrin-G1 (NTNG1), not neurexin. The mechanistic foundation appears misapplied.

**2. Gene naming inconsistency**: NGL-1 is encoded by LRRC4B, but the hypothesis calls it "NGL-1 (LRRC4B)" when in fact NGL-1/LRRC4B and NGL-2/LRRC4C are distinct genes. This suggests potential confusion about which NGL family member is actually being proposed.

**3. Synaptic specificity mechanisms in GBM**: The premise that synaptic specificity "controls" exist to prevent inappropriate synapse formation may not apply to the tumor context. Glioma cells are highly plastic and may simply lack the machinery to exclude inappropriate partners rather than having active inhibitory mechanisms.

**4. Alternative NGL family silencing**: If one NGL is silenced, others (NGL-2, NGL-3/LRRC4C) may compensate, making single-gene restoration ineffective.

### Counter-Evidence

- **NGL-1 expression in neural development**: NGL-1 (LRRC4B) expression is primarily in neurons, not glia. Its relevance to glioma membrane adhesion biology is not established.

- **PMID: 25527634 review**: The citation regarding NGL family silencing in cancer discusses broad gene family dysregulation but does not specifically link NGL-1 loss to synaptic formation in GBM.

### Alternative Explanations

1. **Netrin-G1/G2 guidance molecule loss**: Rather than NGL loss, reduced netrin-G expression could alter the molecular matching between pre- and postsynaptic compartments.

2. **Contactin-1 upregulation**: Contactin-1 is overexpressed in GBM and can engage neuronal partners independently of IgLON family interactions.

3. **Loss of synaptic rejection signals**: Cells may require active "don't touch" signals (like sid1/2 in C. elegans) to prevent synapse formation. Loss of these signals, rather than specific gain of synaptogenic adhesion, may explain the phenomenon.

### Key Falsification Experiments

| Experiment | Expected Result if False |
|------------|-------------------------|
| Distinguish LRRC4B (NGL-1) vs. LRRC4C (NGL-2) expression in GBM | Only NGL-2 is expressed; NGL-1 is irrelevant |
| LRRC4B promoter methylation analysis | No methylation at NGL-1 locus |
| NGL-1 rescue in GSCs | No change in synaptic partner specificity |
| Test if GBM synapses form with wrong neuronal partners | Specificity controls may not exist in the tumor context |

**Revised Confidence: 0.25** (Lowest confidence due to apparent gene misidentification and confusion between NGL family members)

---

## Hypothesis 6: Pentraxin-1 (NPTX1) Secretion

### Specific Weaknesses

**1. Directionality error (critical flaw)**: The hypothesis claims GBM cells secrete NPTX1 to organize AMPA receptor clusters. This is **incorrect**. NPTX1 is a neuronal pentraxin produced specifically by neurons (parvalbumin-expressing interneurons in particular) that organizes AMPA receptors on presynaptic terminals (PMID: 14600253). If GBM secretes NPTX1, it would be an extremely unusual ectopic expression not supported by current literature.

2. **PMID formatting error**: The citation "PMID: 107挑戰 126769" appears corrupted/invalid and cannot be verified. A PubMed search for PMID 107 or similar numbers would return pre-1980s papers irrelevant to pentraxins.

3. **Paracrine loop assumption**: The hypothesis proposes a "feedforward loop" where glioma secretes NPTX1, attracts nerve terminals, receives glutamate, then secretes more NPTX1. However, if neurons are the source of NPTX1, the loop structure is fundamentally reversed.

### Counter-Evidence

- **NPTX1 is a neuronal/oligodendrocyte protein**: Comprehensive expression databases (Allen Brain Atlas, Human Protein Atlas) show NPTX1 expression is restricted to neurons and oligodendrocyte lineage cells. GBM cells do not express NPTX1.

- **NPTX2, not NPTX1, is implicated in cancer**: NPTX2 (Neuronal Pentraxin 2) has been implicated in glioblastoma pathogenesis through different mechanisms (PMID: 29358686).

- **Neuronal pentraxin receptor (NPR) expression**: NPR is expressed primarily on neurons, not GBM cells, suggesting the receptor-ligand interaction would affect neurons rather than tumor cells.

### Alternative Explanations

1. **Neuron-derived NPTX1 mediates synapse formation**: If NPTX1 from neurons organizes presynaptic inputs onto GBM, this would be consistent with the known biology but would make GBM the passive recipient rather than active driver.

2. **Secreted extracellular matrix remodeling**: GBM secretes multiple ECM proteins (tenascin-C, SPARC) that alter the local synaptic environment without specific pentraxin involvement.

3. **Activity-dependent BDNF secretion**: BDNF is activity-dependently released by neurons and promotes synaptic plasticity; similar mechanisms could explain activity-dependent glioma effects.

### Key Falsification Experiments

| Experiment | Expected Result if False |
|------------|-------------------------|
| RNA-seq and proteomics of GSCs for NPTX1 expression | No NPTX1 expression in any GBM subtype |
| scRNA-seq from GBM tumors | NPTX1 transcripts only in neuronal clusters, not tumor cells |
| Anti-NPTX1 blocking antibodies | No effect on synapse density because GBM doesn't secrete NPTX1 |
| Is NPTX1 secretion in the model tumor cell autonomous? | Rescue experiments show neuronal source of NPTX1 |

**Revised Confidence: 0.20** (Lowest confidence due to fundamental biological error regarding cellular source of NPTX1)

---

## Hypothesis 7: GABAergic Neuron "Bypass"

### Specific Weaknesses

**1. Weak mechanistic link**: The hypothesis claims GABABR loss removes a "developmental checkpoint that prevents ectopic synapse formation." This checkpoint has not been described in the literature. GABABR regulates presynaptic neurotransmitter release and some postsynaptic signaling, but there is no evidence GABABR directly prevents ectopic synapse formation.

2. **Baclofen pharmacology concerns**: Baclofen is a GABABR agonist used clinically for spasticity. However:
   - Baclofen does not cross the blood-brain tumor barrier efficiently
   - Systemic baclofen causes significant CNS depression and sedation
   - The therapeutic window for brain tumor applications would be extremely narrow

3. **PMID: 26203161 interpretation**: This paper addresses GABABR in general synaptic plasticity; it does not establish GABABR as a specific barrier to ectopic synapse formation.

4. **PMID: 32209444 details**: This reference requires verification. A 2020 paper on GABAergic signaling in GBM would need to specifically link GABABR loss to synapse formation rather than other effects (inhibition of migration, effects on excitotoxicity, etc.).

### Counter-Evidence

- **GABABR agonists in clinical trials**: Baclofen has been tested in brain tumor patients and shown limited efficacy, suggesting either insufficient CNS penetration or incorrect mechanism.

- **GABAergic signaling promotes GBM invasion**: Some studies suggest GABA acts through GABA-A receptors to promote GBM cell migration (PMID: 25437880). Restoring "inhibitory signaling" might actually worsen outcomes.

- **Activity-dependent vs. activity-independent effects**: The excitation/inhibition balance model (PMID: 38760585) may describe general network hyperexcitability in GBM patients, not specific synapse formation on tumor cells.

### Alternative Explanations

1. **Generalized seizure propensity**: High-neural GBM patients have seizures due to network disruption, not because tumor cells form synapses. The "synaptic integration" may be an epiphenomenon of general network dysfunction.

2. **Peritumoral astrocyte dysfunction**: Loss of astrocytic GABA uptake or glutamate metabolism around tumors could alter E/I balance without affecting tumor-to-neuron synapses.

3. **Neuronal excitability changes**: Rather than affecting tumor synapses, GBM-derived factors (glutamate, ATP) alter neuronal membrane properties, making neurons more likely to fire without actual synaptic restructuring on tumor cells.

### Key Falsification Experiments

| Experiment | Expected Result if False |
|------------|-------------------------|
| qPCR/Western blot for GABBR1/2 in neural vs. non-neural GBM | GABBR expression is equivalent across subtypes |
| Baclofen treatment in orthotopic models | No effect on synapse density or tumor growth |
| GABABR rescue in GSCs | No change in excitatory/inhibitory balance |
| Is the "bypass" mechanism actually about neuronal GABABR, not tumor GABABR? | Neuronal GABABR mediates the effect, not tumor cell GABABR |

**Revised Confidence: 0.30** (Low confidence due to weak mechanistic link, poor drug candidacy, and alternative explanations for E/I imbalance)

---

## Summary of Revised Confidence Scores

| Hypothesis | Original Confidence | Revised Confidence | Primary Concern |
|------------|-------------------|--------------------|--------------------|
| H1: LPHN3 | 0.65 | 0.35 | No direct GBM expression data; developmental pathway generalizability |
| H2: GRIA2/ADAR2 | 0.70 | 0.40 | CP-AMPAR toxicity vs. tumor survival contradiction; limited perampanel efficacy |
| H3: NLGN4X | 0.55 | 0.35 | X-linked sex-specific confound; mischaracterization of NLGN4X function |
| H4: PTPRD | 0.50 | 0.30 | Incomplete mechanism; tumor suppressor paradox |
| H5: NGL-1 | 0.50 | 0.25 | Gene misidentification; NGL-1 not the relevant family member |
| H6: NPTX1 | 0.60 | 0.20 | **Fundamental biological error**: NPTX1 is neuronal, not tumor-derived |
| H7: GABABR | 0.55 | 0.30 | No established "checkpoint" mechanism; poor drug candidacy |

---

## Cross-Cutting Issues Across All Hypotheses

### 1. Reference Quality Concerns
- **PMID:38760585** is cited in 4 of 7 hypotheses but appears to be either a preprint or an extremely recent publication. Its robustness cannot be independently verified.
- **PMID:107挑戰 126769** (H6) contains non-numeric characters and is clearly invalid or corrupted.
- Multiple hypotheses rely heavily on a single citation as the primary evidence for "neural subtype GBM cells exhibit X," suggesting potential circular reasoning.

### 2. Lack of Direct Experimental Evidence
None of the hypotheses provide:
- Direct measurement of synaptic proteins on patient-derived GBM cells
- Electron microscopy demonstrating bona fide synaptic structures
- Functional electrophysiology from GFP+ tumor cells in acute brain slices
- Time-lapse imaging of synapse formation between identified neurons and tumor cells

### 3. Activity Dependence Assumption
All hypotheses assume neuronal activity drives synapse formation. However, an alternative framework is that **glioma cells release synaptogenic factors that induce presynaptic terminals from neurons** (a "bystander" model rather than "synapse formation" model). This would change the therapeutic target from tumor cell receptors to secreted factors.

### 4. The Neural Subtype Specificity Problem
If neuron-to-glioma synapses are specific to "high-neural" GBM, what distinguishes these tumors mechanistically? Most hypotheses propose differential expression of postsynaptic proteins, but:
- This has not been systematically mapped
- Single-cell transcriptomics of neural subtype GBM shows heterogeneous expression of synaptic genes
- The correlation between neural subtype and synapse formation has not been causally established

---

## Recommended Priority for Experimental Validation

Based on this critique, I recommend the following priority:

1. **First priority**: Direct measurement of synaptic structures (EM) and functional synapses (patch clamp from tumor cells) in patient-derived neural-subtype GBM models. Without confirming that bona fide synapses exist, all molecular hypotheses remain speculative.

2. **Second priority**: Unbiased proteomic/transcriptomic profiling of synaptic proteins in matched neural vs. non-neural GBM specimens to identify which adhesion molecules and receptors are actually differentially expressed.

3. **Third priority**: Test H2 (GRIA2) and H1 (LPHN3) with rigorous experiments, as these have the most biologically plausible mechanisms, but address the contradictions (CP-AMPAR toxicity; LPHN3 developmental pathway generalizability) directly.

4. **Hypothesis H6 should be abandoned** in its current form due to fundamental biological error and replaced with investigation of whether neuronal NPTX1 organizes synapses onto GBM cells (which would reverse the proposed mechanism).

---

## Revised Confidence Summary Table

| Rank | Hypothesis | Target | Revised Confidence | Feasibility Assessment |
|------|------------|--------|-------------------|------------------------|
| 1 | H2 | GRIA2/ADAR2 | 0.40 | Medium - addresses real biology but has internal contradictions |
| 2 | H1 | LPHN3/ADGRL3 | 0.35 | Medium - requires direct GBM expression validation |
| 3 | H3 | NLGN4X | 0.35 | Low-Medium - sex-specific confound needs resolution |
| 4 | H4 | PTPRD | 0.30 | Low - pathway incomplete; tumor suppressor confound |
| 5 | H7 | GABBR1/2 | 0.30 | Low - no established "checkpoint" mechanism |
| 6 | H5 | LRRC4B (NGL-1) | 0.25 | Very Low - gene misidentification |
| 7 | H6 | NPTX1 | 0.20 | **Abandon** - fundamental biological error |

The overall confidence that any single molecule drives neuron-to-glioma synapse formation is low (mean revised confidence: 0.31). This reflects both the early-stage nature of the field and the multiple methodological concerns identified in the hypothesis set.